The characteristic CD3+CD56+ CIKs phenotype has been demonstrated to exhibit a major histocompatibility complex (MHC)-unrestricted tumor killing ability, in vitro and in medical practice (14). This evidence concerns the gene NCAM1 and neoplasm.